"Our nomination provides numerous examples of these risks, including unknown impurities, peptide-related impurities, incorrect strengths, and even instances where no semaglutide was present in the product at all," Novo Nordisk spokesperson Jamie Bennet wrote in an email to NPR
It is important to note that including patients with a known history of depression and/or anxiety in such studies could bias the results, as these patients are more prone to experience a new episode, which could be wrongfully attributed to GLP-1 RAs drugs
Taken together, the evidence points to a future where eligibility for GLP-1 treatment could expand significantly as guidelines catch up with the science
Evening Many patients and healthcare providers wonder whether morning or evening injections work better
This may include swelling, pain or discomfort, discoloration, or a rash
Achieve lasting weight loss and metabolic well-being with our online program